ArticleReproductive biology and endocrinology : RB&E2004
Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro.
Article in Reproductive biology and endocrinology : RB&E, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2011Guideline
- What now? A critical evaluation of over 20 years of clinical and research experience with 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.American journal of obstetrics & gynecology MFM · 2023Review
- Progesterone, via yes-associated protein, promotes cardiomyocyte proliferation and cardiac repair.Cell proliferation · 2020Article
- Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.American journal of obstetrics and gynecology · 2015Article
- Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.American journal of obstetrics and gynecology · 2013Review
- Metabolism of 17-alpha-hydroxyprogesterone caproate by human placental mitochondria.Reproductive sciences (Thousand Oaks, Calif.) · 2012Article
- Actions of progestins for the inhibition of cervical ripening and uterine contractions to prevent preterm birth.Facts, views & vision in ObGyn · 2012Review
- 17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.Paediatric drugs · 2011Review
- Progestin treatment for the prevention of preterm birth.Acta obstetricia et gynecologica Scandinavica · 2011Review
- Effect of 17-alpha hydroxyprogesterone caproate on the production of tumor necrosis factor-alpha and the expression of cyclooxygenase-2 in lipopolysaccharide-treated gravid human myometrial explants.Journal of perinatology : official journal of the California Perinatal Association · 2010Article
- Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle.American journal of obstetrics and gynecology · 2010Article
- Human decidual cell Toll-like receptor signaling in response to endotoxin: the effect of progestins.American journal of obstetrics and gynecology · 2008Article
- New research models and novel signal analysis in studies on preterm labor: a key to progress?BMC pregnancy and childbirth · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background17 alpha-hydroxyprogesterone caproate (17P) administration reportedly improves outcome for women with a previous spontaneous preterm delivery. This study, using in vitro strips of human uterine smooth muscle, aimed to investigate the direct non-genomic effects of 17P on spontaneous and induced contractions in tissues obtained during pregnancy, and in the non-pregnant state.
methodsBiopsies of human myometrium were obtained at elective cesarean section, and from hysterectomy specimens, and dissected strips suspended for isometric recordings. The effects of 17P (1 nmol/L -10 micro mol/L) on spontaneous and agonist-induced (oxytocin 0.5 nmol/L for pregnant, phenylephrine 10 micromol/L for non-pregnant) contractions were measured. Integrals of contractile activity, including the mean maximal inhibition values (MMI) observed at the maximal concentration, were compared with those from simultaneously run control strips.
resultsThere was no significant direct effect exerted by 17P on pregnant or non-pregnant human myometrial contractility. The MMI +/- SEM for spontaneous contractions in pregnant myometrium was 4.9% +/- 7.2 (n = 6; P = 0.309) and for oxytocin-induced contractions was 2.2% +/- 1.3 (n = 6; P = 0.128). For non-pregnant myometrium, the MMI +/- SEM for spontaneous contractions was 8.8% +/- 11.0 (n = 6; P = 0.121) and for phenylephrine induced contractions was -7.9% +/- 6.5 (n = 6; P = 0.966).
conclusionsThe putative benefits of 17P for preterm labor prevention are not achieved, even partially, by a direct utero-relaxant effect. These findings outline the possibility that genomic effects of 17P, achieved over long periods of administration, are required for its reported therapeutic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.